- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03327740
PRJ2203: Dolutegravir Post Authorization Safety Study (PASS)
February 5, 2020 updated by: ViiV Healthcare
A Prospective Observational Cohort Study to Monitor and Compare the Occurrence of Hypersensitivity Reaction and Hepatotoxicity in Patients Receiving Dolutegravir (With and Without Abacavir) or Other Integrase Inhibitors (With or Without Abacavir)
Dolutegravir (DTG) is recommended for both treatment-naïve and treatment-experienced, HIV infected adults and paediatric subjects aged 12 years and older and weighing at least 40 kg.
One case of suspected DTG hypersensitivity (HSR) reaction from among over 1500 subjects exposed to the drug at the time of submission in 4Q2012, has been identified; this subject experienced a diffuse maculopapular rash with fever and elevated liver enzymes.
Isolated rash was uncommon in the DTG programme with less than 1% of clinical trial subjects experiencing treatment related rash.
The pharmacovigilance strategy for DTG and DTG-containing products is to implement a post-marketing risk management program to further quantify the risk of HSR and compare it to that of other integrase inhibitors, and to possibly determine associated risk factors.
In addition, the post-authorization safety study will monitor and compare hepatotoxicity and severe skin rash following initiation of DTG or other integrase inhibitor (raltegravir (RAL) or elvitegravir (EGV) based antiretroviral regimens (ARV).
Further to be able to distinguish the above symptoms and reactions caused by DTG or the other integrase inhibitor regimen from that of abacavir (ABC), known to cause hypersensitivity reaction, the integrase inhibitor groups will be compared in combinations with and without ABC.
This five year-long safety study will be conducted through collaboration with EuroSIDA, a well established prospective observational cohort study of more than 18,200 subjects followed in 107 hospitals in 31 European countries, plus Israel and Argentina.
This is a five year-long non-interventional prospective cohort study nested within the EuroSIDA study.
The study population will include HIV positive subjects over the age of 16 years from EuroSIDA clinical sites, who are new users of DTG or other integrase inhibitors with and without ABC.
Following initiation of DTG with ABC based antiretroviral regimen or DTG without ABC or regimens containing other integrase inhibitors (RAL, EGV) with or without ABC or any other DTG based ARV regimen as monotherapy or two-drug regimens, the study will aim to a) Monitor and compare hypersensitivity reaction, b) Monitor and compare hepatotoxicity, and c) Monitor and compare severe skin rash among all subjects discontinuing DTG or other integrase inhibitor regimens for any reason.
Study Overview
Status
Completed
Conditions
Study Type
Observational
Enrollment (Anticipated)
1
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
17 years and older (Child, Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
HIV positive subjects over the age of 16 years from EuroSIDA clinical sites, who are new users of DTG or users of other integrase inhibitor regimens (RAL and EGV).
Description
Inclusion Criteria:
- New users of DTG or users of other integrase inhibitor regimens (RAL and EGV)
Exclusion Criteria:
- None
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Subjects on DTG based ARV with ABC
These are subjects who begin a DTG based ARV regimen that includes ABC
|
ARV regimens containing DTG and ABC
|
Subjects that start DTG based ARV regimen but without ABC
These are subjects who begin a DTG-based ARV regimen that does not contain ABC
|
DTG based ARV regimens that do not contain ABC
|
Subjects on other integrase inhibitor based regimen with ABC
These are subjects who begin other integrase inhibitor based regimens (RAL and EGV) that contains ABC
|
RAL or EGV based regimens containing ABC
|
Subjects on other integrase inhibitor based regimen but no ABC
These are subjects that start non-ABC containing RAL or EGV based regimens
|
RAL or EGV based ARV regimens that do not contain ABC
|
Subjects that start any other DTG based ARV regimen
These are subjects who begin any other DTG based ARV regimen that will include DTG as monotherapy or two-drug regimens
|
Any other DTG based ARV regimens including DTG as monotherapy or two-drug regimens.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of subjects with occurrence of hypersensitivity reactions (HSR), of any grade
Time Frame: Up to 5 years
|
Hypersensitivity reactions including fever, rash, gastrointestinal symptoms, constitutional symptoms, respiratory symptoms and eosinophilia will be summarized.
|
Up to 5 years
|
Number of subjects with hepatic dysfunction
Time Frame: Up to 5 years
|
Hepatic dysfunction will be indicated by liver chemistry tests
|
Up to 5 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 30, 2014
Primary Completion (Actual)
December 31, 2019
Study Completion (Actual)
December 31, 2019
Study Registration Dates
First Submitted
October 27, 2017
First Submitted That Met QC Criteria
October 27, 2017
First Posted (Actual)
October 31, 2017
Study Record Updates
Last Update Posted (Actual)
February 6, 2020
Last Update Submitted That Met QC Criteria
February 5, 2020
Last Verified
February 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immunologic Deficiency Syndromes
- Immune System Diseases
- Slow Virus Diseases
- HIV Infections
- Acquired Immunodeficiency Syndrome
Other Study ID Numbers
- 201177
- PRJ2203 (Other Identifier: GSK)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Infection, Human Immunodeficiency Virus I
-
bioLytical LaboratoriesNot yet recruitingHuman Immunodeficiency Virus I Infection | Human Immunodeficiency Virus II Infection
-
ViiV HealthcareGlaxoSmithKlineCompletedInfection, Human Immunodeficiency Virus IUnited States, Spain, Canada, Russian Federation, Romania, Belgium, South Africa
-
MacroGenicsNational Institute of Allergy and Infectious Diseases (NIAID); National Institutes... and other collaboratorsActive, not recruitingHuman Immunodeficiency Virus I Infection | Immunodeficiency Virus Type 1, Human | Human Immunodeficiency Virus Type 1United States
-
GlaxoSmithKlineCompletedHIV Infection | HIV-1 Infection | Infection, Human Immunodeficiency Virus INetherlands, Finland, Ireland, Portugal, Switzerland
-
ViiV HealthcareTerminatedHIV Infection | Infection, Human Immunodeficiency Virus IUnited States, France, Canada, Germany, Italy, Belgium, United Kingdom, Portugal, Spain
-
GlaxoSmithKlineCompletedHIV Infection | Infection, Human Immunodeficiency Virus IGermany, Belgium, United Kingdom, Spain, Ireland, Italy, France, Austria, Denmark, Netherlands, Switzerland, Portugal, Latvia
-
ViiV HealthcareCompletedHIV Infection | Infection, Human Immunodeficiency Virus IUnited States, Spain, Germany, Canada, Belgium, Portugal, Italy, France, United Kingdom
-
ViiV HealthcareCompletedHIV Infection | Infection, Human Immunodeficiency Virus IUnited States, Puerto Rico, Costa Rica, Panama
-
ViiV HealthcareTerminatedHIV-1 Infection | Infection, Human Immunodeficiency Virus IUnited States, France, Germany, Canada, Italy, Australia, Belgium, Portugal, Puerto Rico, Romania, United Kingdom
-
ViiV HealthcareGlaxoSmithKlineCompletedHIV-1 Infection | Infection, Human Immunodeficiency Virus IGermany, Spain, France, Belgium, United Kingdom, Italy, Romania, Russian Federation, Switzerland
Clinical Trials on DTG based ARV regimen with ABC
-
ViiV HealthcareGlaxoSmithKline; PPDCompletedInfection, Human Immunodeficiency VirusUnited States, Canada, Puerto Rico
-
Juan A. ArnaizUnknown
-
ViiV HealthcareGlaxoSmithKlineCompletedHIV InfectionsUnited States, Germany, Spain, France, Australia, Canada, Belgium, Netherlands, United Kingdom, Japan
-
Sun Yat-sen UniversityRecruitingGlucose Metabolism Disorders | Diabetes Mellitus, Type 2 | Diabetes Mellitus | Endocrine System Diseases | Metabolic DiseaseChina
-
Jian ChenRecruitingThymic Epithelial Tumor | Radiotherapy Side Effect | Carbon Ion Radiotheray | Heavy Ion RadiotherapyChina
-
InSource DiagnosticsSyntactxUnknownTarget Drug-related Adverse EventsUnited States
-
First People's Hospital of HangzhouNot yet recruitingBiliary Tract Cancer | Gemcitabine | Immune Checkpoint InhibitorsChina